MARK L PERRY Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for MARK L PERRY.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of MARK L PERRY. MARK L PERRY is Director in ARCA biopharma, Inc. ($ABIO) and Director in NVIDIA CORP ($NVDA) and Director in MyoKardia Inc ($MYOK) and Director in Global Blood Therapeutics, Inc. ($GBT).
Latest Insider Trading Transactions of MARK L PERRY
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ABIO, GBT, MYOK, NVDA
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 06 2021 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 556.98 | 1,400 | 779,772 | 6,631 | 8 K to 6.6 K (-17.43 %) |
Apr 06 2021 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 556.46 | 4,704 | 2,617,588 | 8,031 | 12.7 K to 8 K (-36.94 %) |
Nov 19 2020 | MYOK | MyoKardia, Inc. | PERRY MARK L | Director | Option Exercise | D | 100.27 | 3,000 | 300,810 | 0 | |
Nov 19 2020 | MYOK | MyoKardia, Inc. | PERRY MARK L | Director | Option Exercise | D | 47.77 | 6,600 | 315,282 | 0 | |
Nov 19 2020 | MYOK | MyoKardia, Inc. | PERRY MARK L | Director | Option Exercise | D | 48.85 | 11,000 | 537,350 | 0 | |
Nov 19 2020 | MYOK | MyoKardia, Inc. | PERRY MARK L | Director | Option Exercise | D | 14.00 | 11,000 | 154,000 | 0 | |
Nov 19 2020 | MYOK | MyoKardia, Inc. | PERRY MARK L | Director | Option Exercise | D | 13.60 | 11,000 | 149,600 | 0 | |
Nov 19 2020 | MYOK | MyoKardia, Inc. | PERRY MARK L | Director | Option Exercise | D | 10.00 | 21,800 | 218,000 | 0 | |
Nov 19 2020 | MYOK | MyoKardia, Inc. | PERRY MARK L | Director | Sell | U | 0.00 | 29,508 | 0 | 0 | 29.5 K to 0 (-100.00 %) |
Nov 19 2020 | MYOK | MyoKardia, Inc. | PERRY MARK L | Director | Option Exercise | D | 100.27 | 3,000 | 300,810 | 0 | |
Nov 19 2020 | MYOK | MyoKardia, Inc. | PERRY MARK L | Director | Option Exercise | D | 47.77 | 6,600 | 315,282 | 0 | |
Nov 19 2020 | MYOK | MyoKardia, Inc. | PERRY MARK L | Director | Option Exercise | D | 48.85 | 11,000 | 537,350 | 0 | |
Nov 19 2020 | MYOK | MyoKardia, Inc. | PERRY MARK L | Director | Option Exercise | D | 14.00 | 11,000 | 154,000 | 0 | |
Nov 19 2020 | MYOK | MyoKardia, Inc. | PERRY MARK L | Director | Option Exercise | D | 13.60 | 11,000 | 149,600 | 0 | |
Nov 19 2020 | MYOK | MyoKardia, Inc. | PERRY MARK L | Director | Option Exercise | D | 10.00 | 21,800 | 218,000 | 0 | |
Nov 19 2020 | MYOK | MyoKardia, Inc. | PERRY MARK L | Director | Sell | U | 0.00 | 29,508 | 0 | 0 | 29.5 K to 0 (-100.00 %) |
Jun 22 2020 | MYOK | MyoKardia, Inc. | PERRY MARK L | Director | Option Exercise | A | 0.00 | 1,800 | 0 | 1,800 | |
Jun 22 2020 | MYOK | MyoKardia, Inc. | PERRY MARK L | Director | Option Exercise | A | 100.27 | 3,000 | 300,810 | 3,000 | |
Jun 19 2020 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Option Exercise | A | 0.00 | 3,037 | 0 | 3,037 | |
Jun 19 2020 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Option Exercise | A | 0.00 | 3,037 | 0 | 3,037 | |
Jun 19 2020 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Option Exercise | A | 64.75 | 5,247 | 339,743 | 5,247 | |
Jun 19 2020 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Option Exercise | A | 64.75 | 5,247 | 339,743 | 5,247 | |
Jun 19 2020 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Option Exercise | M | 0.00 | 4,800 | 0 | 0 | |
Jun 19 2020 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Option Exercise | M | 0.00 | 4,800 | 0 | 0 | |
Jun 19 2020 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Buy | M | 0.00 | 4,800 | 0 | 31,228 | 26.4 K to 31.2 K (+18.16 %) |
Jun 19 2020 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Buy | M | 0.00 | 4,800 | 0 | 31,228 | 26.4 K to 31.2 K (+18.16 %) |
Jun 16 2020 | MYOK | MyoKardia, Inc. | PERRY MARK L | Director | Option Exercise | M | 0.00 | 2,300 | 0 | 0 | |
Jun 16 2020 | MYOK | MyoKardia, Inc. | PERRY MARK L | Director | Buy | M | 0.00 | 2,300 | 0 | 27,708 | 25.4 K to 27.7 K (+9.05 %) |
Jun 12 2020 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Grant | A | 0.00 | 712 | 0 | 12,735 | 12 K to 12.7 K (+5.92 %) |
May 29 2020 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 342.73 | 600 | 205,637 | 12,023 | 12.6 K to 12 K (-4.75 %) |
May 29 2020 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 341.54 | 300 | 102,463 | 12,623 | 12.9 K to 12.6 K (-2.32 %) |
May 29 2020 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 340.38 | 300 | 102,113 | 12,923 | 13.2 K to 12.9 K (-2.27 %) |
May 29 2020 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 339.16 | 600 | 203,494 | 13,223 | 13.8 K to 13.2 K (-4.34 %) |
May 29 2020 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 338.09 | 600 | 202,856 | 13,823 | 14.4 K to 13.8 K (-4.16 %) |
May 29 2020 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 336.97 | 800 | 269,578 | 14,423 | 15.2 K to 14.4 K (-5.26 %) |
May 29 2020 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 335.87 | 1,202 | 403,712 | 15,223 | 16.4 K to 15.2 K (-7.32 %) |
May 29 2020 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 333.45 | 404 | 134,714 | 16,425 | 16.8 K to 16.4 K (-2.40 %) |
May 29 2020 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 332.20 | 1,100 | 365,421 | 16,829 | 17.9 K to 16.8 K (-6.14 %) |
May 29 2020 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 331.31 | 2,200 | 728,886 | 17,929 | 20.1 K to 17.9 K (-10.93 %) |
May 29 2020 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 330.32 | 1,600 | 528,506 | 20,129 | 21.7 K to 20.1 K (-7.36 %) |
May 29 2020 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 329.28 | 1,300 | 428,062 | 21,729 | 23 K to 21.7 K (-5.65 %) |
May 29 2020 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 327.93 | 802 | 263,002 | 23,029 | 23.8 K to 23 K (-3.37 %) |
May 29 2020 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 326.51 | 400 | 130,605 | 23,831 | 24.2 K to 23.8 K (-1.65 %) |
May 13 2020 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Option Exercise | M | 28.45 | 15,000 | 426,750 | 0 | |
May 13 2020 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Option Exercise | M | 18.85 | 15,000 | 282,750 | 0 | |
May 13 2020 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Option Exercise | M | 20.00 | 8,600 | 172,000 | 0 | |
May 13 2020 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Option Exercise | M | 20.00 | 15,000 | 300,000 | 0 | |
May 13 2020 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Sell | S | 79.17 | 1,295 | 102,522 | 26,428 | 27.7 K to 26.4 K (-4.67 %) |
May 13 2020 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Sell | S | 78.65 | 34,698 | 2,728,932 | 27,723 | 62.4 K to 27.7 K (-55.59 %) |
May 13 2020 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Sell | S | 77.71 | 13,024 | 1,012,138 | 62,421 | 75.4 K to 62.4 K (-17.26 %) |
May 13 2020 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Sell | S | 76.28 | 600 | 45,771 | 75,445 | 76 K to 75.4 K (-0.79 %) |
May 13 2020 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Sell | S | 75.43 | 1,350 | 101,833 | 76,045 | 77.4 K to 76 K (-1.74 %) |
May 13 2020 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Sell | S | 74.01 | 2,633 | 194,865 | 77,395 | 80 K to 77.4 K (-3.29 %) |
May 13 2020 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Buy | M | 28.45 | 15,000 | 426,750 | 80,028 | 65 K to 80 K (+23.07 %) |
May 13 2020 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Buy | M | 18.85 | 15,000 | 282,750 | 65,028 | 50 K to 65 K (+29.98 %) |
May 13 2020 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Buy | M | 20.00 | 8,600 | 172,000 | 50,028 | 41.4 K to 50 K (+20.76 %) |
May 13 2020 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Buy | M | 20.00 | 15,000 | 300,000 | 41,428 | 26.4 K to 41.4 K (+56.76 %) |
Feb 20 2020 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 296.89 | 200 | 59,378 | 24,231 | 24.4 K to 24.2 K (-0.82 %) |
Feb 20 2020 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 296.36 | 1,459 | 432,389 | 24,431 | 25.9 K to 24.4 K (-5.64 %) |
Feb 20 2020 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 295.51 | 505 | 149,233 | 25,890 | 26.4 K to 25.9 K (-1.91 %) |
Feb 20 2020 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 294.19 | 400 | 117,676 | 26,395 | 26.8 K to 26.4 K (-1.49 %) |
Feb 20 2020 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 292.99 | 1,201 | 351,881 | 26,795 | 28 K to 26.8 K (-4.29 %) |
Feb 20 2020 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 291.76 | 615 | 179,432 | 27,996 | 28.6 K to 28 K (-2.15 %) |
Feb 20 2020 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 290.68 | 1,302 | 378,465 | 28,611 | 29.9 K to 28.6 K (-4.35 %) |
Feb 20 2020 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 289.68 | 2,013 | 583,126 | 29,913 | 31.9 K to 29.9 K (-6.31 %) |
Feb 20 2020 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 288.71 | 1,057 | 305,166 | 31,926 | 33 K to 31.9 K (-3.20 %) |
Jun 20 2019 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Option Exercise | A | 0.00 | 4,800 | 0 | 4,800 | |
Jun 20 2019 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Option Exercise | A | 56.30 | 7,500 | 422,250 | 7,500 | |
Jun 17 2019 | MYOK | MyoKardia Inc | PERRY MARK L | Director | Option Exercise | A | 0.00 | 2,300 | 0 | 2,300 | |
Jun 17 2019 | MYOK | MyoKardia Inc | PERRY MARK L | Director | Option Exercise | A | 47.17 | 6,600 | 311,322 | 6,600 | |
May 28 2019 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Grant | A | 0.00 | 1,258 | 0 | 32,983 | 31.7 K to 33 K (+3.97 %) |
Jun 22 2018 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Option Exercise | A | 42.25 | 15,000 | 633,750 | 15,000 | |
Jun 14 2018 | MYOK | MyoKardia Inc | PERRY MARK L | Director | Option Exercise | A | 48.85 | 11,000 | 537,350 | 11,000 | |
May 21 2018 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Grant | A | 0.00 | 963 | 0 | 31,725 | 30.8 K to 31.7 K (+3.13 %) |
Feb 13 2018 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 227.93 | 17,307 | 3,944,805 | 30,762 | 48.1 K to 30.8 K (-36.00 %) |
Aug 16 2017 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 162.24 | 16,281 | 2,641,369 | 48,069 | 64.4 K to 48.1 K (-25.30 %) |
Jun 22 2017 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Option Exercise | A | 28.45 | 15,000 | 426,750 | 15,000 | |
May 26 2017 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Grant | A | 0.00 | 2,058 | 0 | 64,350 | 62.3 K to 64.4 K (+3.30 %) |
May 26 2017 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Gift | G | 0.00 | 10,000 | 0 | 40,000 | 50 K to 40 K (-20.00 %) |
Jul 15 2016 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Option Exercise | M | 17.78 | 35,000 | 622,300 | 0 | |
Jul 15 2016 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Option Exercise | M | 17.78 | 35,000 | 622,300 | 0 | |
Jul 15 2016 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 52.93 | 35,000 | 1,852,463 | 62,292 | 97.3 K to 62.3 K (-35.97 %) |
Jul 15 2016 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 52.93 | 35,000 | 1,852,463 | 62,292 | 97.3 K to 62.3 K (-35.97 %) |
Jul 15 2016 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Buy | M | 17.78 | 35,000 | 622,300 | 97,292 | 62.3 K to 97.3 K (+56.19 %) |
Jul 15 2016 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Buy | M | 17.78 | 35,000 | 622,300 | 97,292 | 62.3 K to 97.3 K (+56.19 %) |
Jun 09 2016 | MYOK | MyoKardia Inc | PERRY MARK L | Director | Option Exercise | A | 13.60 | 11,000 | 149,600 | 11,000 | |
May 23 2016 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Grant | A | 0.00 | 6,213 | 0 | 62,292 | 56.1 K to 62.3 K (+11.08 %) |
Jan 07 2016 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Buy | P | 20.00 | 5,000 | 100,000 | 26,428 | 21.4 K to 26.4 K (+23.33 %) |
Nov 16 2015 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Option Exercise | M | 12.46 | 40,000 | 498,400 | 0 | |
Nov 16 2015 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Sell | S | 30.49 | 40,000 | 1,219,704 | 56,079 | 96.1 K to 56.1 K (-41.63 %) |
Nov 16 2015 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Buy | M | 12.46 | 40,000 | 498,400 | 96,079 | 56.1 K to 96.1 K (+71.33 %) |
Nov 05 2015 | MYOK | MyoKardia Inc | PERRY MARK L | Director | Buy | P | 10.00 | 5,000 | 50,000 | 25,408 | 20.4 K to 25.4 K (+24.50 %) |
Oct 30 2015 | MYOK | MyoKardia Inc | PERRY MARK L | Director | Option Exercise | A | 10.00 | 21,800 | 218,000 | 21,800 | |
Aug 13 2015 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Option Exercise | A | 20.00 | 8,600 | 172,000 | 8,600 | |
Aug 13 2015 | GBT | Global Blood Thera ... | PERRY MARK L | Director | Option Exercise | A | 20.00 | 15,000 | 300,000 | 15,000 | |
May 26 2015 | NVDA | NVIDIA CORP | PERRY MARK L | Director | Grant | A | 0.00 | 10,283 | 0 | 56,079 | 45.8 K to 56.1 K (+22.45 %) |
May 26 2005 | ABIO | ARCA biopharma, In ... | PERRY MARK L | Director | Option Exercise | A | 6.73 | 15,000 | 100,950 | 15,000 | |
Mar 25 2005 | ABIO | ARCA biopharma, In ... | PERRY MARK L | Director | Option Exercise | A | 6.50 | 25,000 | 162,500 | 25,000 | |
May 10 2004 | ABIO | ARCA biopharma, In ... | PERRY MARK L | Director | Option Exercise | A | 11.11 | 7,500 | 83,325 | 7,500 |
Page: 1